ANEB — Anebulo Pharmaceuticals Inc
NASDAQ · Healthcare · Biotechnology
$0.30
-$0.02 (-4.76%)
Anebulo Pharmaceuticals Inc (ANEB) is a biotechnology company listed on NASDAQ. It is led by Richard Anthony Cunningham, based in 1017 Ranch Road 620 South, Lakeway, TX, United States, 78734, with about 2 employees. Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.
Net income was -$2.2M. ANEB currently screens at market cap $15.3M.
Use this ANEB page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ANEB quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ANEB SEC filings page. Lician reads the product cache first so this HTML stays unique to Anebulo Pharmaceuticals Inc even when a live quote feed is slow.
About Anebulo Pharmaceuticals Inc
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.
ANEB Key Statistics
Market Cap
$15.29M
Volume
100
Previous Close
$0.31
Day Range
$0.33 – $0.33
EPS
-$0.25
Revenue
$0.00
Net Income
-$8.48M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
2
ANEB Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$8.48M | -$8.20M | -$11.73M | -$6.83M |
| EPS (Diluted) | -$0.25 | -$0.32 | -$0.47 | $0.29 |
Total Assets
$12.15M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$11.63M
Operating Cash Flow
-$6.35M
Free Cash Flow
$0.00
Anebulo Pharmaceuticals Inc Company Information
- CEO & Director
- Richard Anthony Cunningham
- Headquarters
- 1017 Ranch Road 620 South, Lakeway, TX, United States, 78734
- Website
- www.anebulo.com
- Phone
- 512 598 0931
- IPO / Founded
- 2021-05-07
- Sector
- Healthcare
- Industry
- Biotechnology